NEW YORK, December 24, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Acorda Therapeutics, Inc. (NASDAQ: ACOR), Centene Corp. (NYSE: CNC), Neogen Corp. (NASDAQ: NEOG), ImmunoGen, Inc. (NASDAQ: IMGN), and West Pharmaceutical Services, Inc. (NYSE: WST). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Acorda Therapeutics, Inc. Research Report
On December 19, 2013, Acorda Therapeutics, Inc. (Acorda) announced that the European Patent Office (EPO) Opposition Division has upheld amended claims covering a sustained release formulation of fampridine (trade name: FAMPYRA®), also known as dalfampridine or 4-aminopyridine, for improving walking speed in patients with multiple sclerosis (MS) with twice daily dosing at 10 mg. According to the Company, the decision of the Opposition Division is open to appeal. Ron Cohen, M.D., Acorda's President and CEO, commented, "We are pleased that the Opposition Division has recognized the validity of our patent claims for FAMPYRA." The Full Research Report on Acorda Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Centene Corp. Research Report
On December 18, 2013, Centene Corp. (Centene) announced that it has entered into a definitive agreement to acquire a majority stake in Fidelis SecureCare of Michigan, Inc. (Fidelis SecureCare), a subsidiary of Fidelis SeniorCare, Inc. (Fidelis). Centene informed that Fidelis SecureCare was recently chosen by the Michigan Department of Community Health as one of six health plans for offering integrated healthcare services to members dually eligible for Medicare and Medicaid in Macomb and Wayne counties. The Company stated that under the arrangement, Centene and Fidelis will own and operate the Fidelis SecureCare Michigan health plan. Jesse N. Hunter, Executive Vice President and Chief Business Development Officer, Centene, stated, "This announcement marks our entry into a fourth market serving dual-eligible populations. Centene and Fidelis share a common commitment of providing locally-driven, comprehensive care focused on the whole health of the individuals we serve." Centene reported that the transaction is expected to close during Q4 2014, subject to certain closing conditions including regulatory approvals, and will involve cash purchase price payments contingent on the performance of the plan during 2015. The Full Research Report on Centene Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Neogen Corp. Research Report
On December 19, 2013, Neogen Corp. (Neogen) released its Q2 FY 2014 results (period ended November 30, 2013). Neogen registered total revenues of $59.6 million, up 17.5% YoY. The Company posted net income of $6.2 million in Q2 FY 2014, compared to $6.8 million in Q2 FY 2013. Neogen reported diluted EPS of $0.17 for the quarter, compared to $0.19 in Q2 FY 2013. James Herbert, Neogen's CEO and Chairman, stated, "We are pleased to report strong second quarter revenue increases, the result of broad-based organic sales growth throughout our worldwide markets, and the efficient integration of recent acquisitions into our operations." Steve Quinlan, Neogen's CFO, added, "Our balance sheet remains strong, with no debt and the financial strength to allow us to continue to reinvest in the business while pursuing a number of growth strategies moving forward." The Full Research Report on Neogen Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ImmunoGen, Inc. Research Report
On December 9, 2013, ImmunoGen, Inc. (ImmunoGen) announced the first clinical findings with SAR650984 in an oral presentation at the American Society of Hematology (ASH) annual meeting. ImmunoGen reported data from an ongoing Phase I trial assessing the CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy. The Company stated that SAR650984 was initially developed by ImmunoGen and was licensed to Sanofi under collaboration between the Companies. ImmunoGen stated that SAR650984 was found to have a favorable safety profile. John Lambert, PhD, ImmunoGen Executive Vice President and Chief Scientific Officer, said, "It is impressive that so many objectives responses - including complete responses - were seen with SAR650984 when administered as a single agent to patients with such heavily pretreated multiple myeloma. The SAR650984 antibody was selected for development because of its notable anticancer activity in preclinical models, particularly its pronounced ability to directly kill cancer cells through induction of apoptosis." The Full Research Report on ImmunoGen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
West Pharmaceutical Services, Inc. Research Report
On December 19, 2013, West Pharmaceutical Services, Inc. (West) announced that its Board of Directors has approved the payment of a Q1 2014 cash dividend of $0.10 per share. West added that the cash dividend is payable on February 5, 2014 to shareholders of record on January 22, 2014. The Full Research Report on West Pharmaceutical Services, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner